Clinical Trials Logo

Clinical Trial Summary

A Phase 1 dose escalation study to evaluate APR003 in patients with advanced colorectal cancer (CRC) with malignant liver lesions


Clinical Trial Description

APR003 is a small molecule TLR7 agonist that concentrates in the GI, and liver with limited systemic exposure. It is designed to increase the therapeutic window of a TLR7 agonist by minimizing the side-effects associated with generalized systemic immune activation and inflammation. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04645797
Study type Interventional
Source Apros Therapeutics, Inc
Contact
Status Completed
Phase Phase 1
Start date January 20, 2021
Completion date January 9, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT04582981 - Fruquintinib and Raltitrexed Versus Fruquintinib Monotherapy in Advanced Colorectal Cancer Phase 2
Active, not recruiting NCT04164069 - Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab Phase 1
Terminated NCT05648006 - First-line Maintenance of OH2 Injection for Advanced Colorectal Cancer Phase 2
Active, not recruiting NCT04771715 - Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Patients With Advanced Colorectal Cancer
Recruiting NCT05733000 - CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors Phase 2
Active, not recruiting NCT02983578 - Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer Phase 2
Completed NCT01208194 - Efficacy Study of a Maintenance Therapy With Immunomodulator MGN1703 in Patients With Advanced Colorectal Carcinoma Phase 2
Recruiting NCT05967533 - The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors Phase 1
Recruiting NCT05894694 - Survival Benefit of Compound Kushen Injection in the Treatment of Advanced Colorectal Cancer Phase 4
Recruiting NCT04705818 - Combining Epigenetic And Immune Therapy to Beat Cancer. Phase 2
Not yet recruiting NCT05883683 - Molecular Study and Precision Medicine for Colorectal Cancer
Recruiting NCT05759923 - First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients With Selected Advanced and/or Metastatic Solid Tumours Phase 1
Completed NCT01277406 - 4SC-201 (Resminostat) in Advanced Colorectal Carcinoma Phase 1/Phase 2
Recruiting NCT05406206 - Hepatic Arterial Infusion Chemotherapy With Fruquintinib for Colorectal Cancer Liver Metastases As Third-line Therapy Phase 2
Active, not recruiting NCT04109924 - TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study Phase 2
Recruiting NCT04704661 - Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial Phase 1
Recruiting NCT05969860 - At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer Phase 2
Recruiting NCT05200442 - A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer Phase 1/Phase 2
Completed NCT00499850 - Phase I FOLFOX Combination Phase 1
Active, not recruiting NCT04535401 - Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines Phase 1